Anesthesiology

Pacira BioSciences Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Research, Sale, Anesthesiology, PDUFA, Tax, PIN, Chronic pain, Bupivacaine, 340B Drug Pricing Program, SG, Telephone, Conference, GAAP, Doctor of Philosophy, Health, R, Society, Bank statement, Growth, Interest, ASA, Nerve block, Webcast, Health care, Depreciation, Conference call, Investment, American Society of Anesthesiologists, Table, Bank, Online shopping, Management, Video game, Reinsurance, Pharmaceutical industry, EBITDA, MD

TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the third quarter of 2023.

Key Points: 
  • ET --
    TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the third quarter of 2023.
  • Total revenues were $163.9 million in the third quarter of 2023, versus $167.5 million reported for the third quarter of 2022.
  • Third quarter 2023 iovera° net product sales were $5.3 million, versus $4.5 million reported for the third quarter of 2022.
  • The Pacira management team will host a conference call to discuss the company’s financial results and recent developments today, Thursday, November 2, 2023, at 8:30 a.m.

US Anesthesia Drugs and Devices Market Set to Reach $6.83 Billion in 2023, Driven by Growing Healthcare Expenditure - ResearchAndMarkets.com

Retrieved on: 
Monday, November 6, 2023
Pharmaceutical, Health, Medical Devices, Patient, Headache, Ageing, Anesthesiology, Pain, KKR, Vomiting, Abdominal ultrasonography, Somnolence, Prevalence, AstraZeneca, Conditional sentence, Lidocaine, Anesthetic, Shivering, MAC, Envision Healthcare, Nausea, 3M, Abbott Laboratories, General Electric Company, SunMed BRT station, Growth, Fungal infection, TeamHealth, COVID-19, Inhalation, Risk, AbbVie, Device, Benzocaine, Consciousness, Becton, Dickinson and Company headquarters, Blackstone, Braun, Baxter International, Ventilation, Central nervous system, ICU Medical, ICU, Pharmaceutical industry, Dentistry, Bupivacaine, Prilocaine, Anesthesia, Ropivacaine

The US anesthesia drugs and devices market is divided into two primary segments: anesthesia drugs and anesthesia devices.

Key Points: 
  • The US anesthesia drugs and devices market is divided into two primary segments: anesthesia drugs and anesthesia devices.
  • Among these segments, anesthesia drugs currently hold the majority share, while the anesthesia devices segment is expected to experience substantial growth due to increased healthcare expenditure in the region.
  • In terms of types, the US anesthesia drugs market is categorized into General, Local, and other anesthesia.
  • The development of novel anesthesia drugs through pharmaceutical R&D is expected to create growth opportunities in the "other anesthesia drugs" segment.

American Association for Respiratory Care Honors Tri-anim Health Services with 2023 Zenith Award

Retrieved on: 
Monday, October 30, 2023
Pulmonology, Customer, Anesthesiology, Health, Advertising, Caregiver, Hospital, AARC, Nursing, Anesthesia, American Association for Respiratory Care, Nursing care plan, Sarnov

DUBLIN, Ohio , Oct. 30, 2023 /PRNewswire/ -- Tri-anim Health Services, a Sarnova company and a leading distributor of specialized respiratory, anesthesia, and critical care supplies, services and equipment, has been honored with the prestigious 2023 Zenith Award by the American Association for Respiratory Care (AARC).

Key Points: 
  • DUBLIN, Ohio , Oct. 30, 2023 /PRNewswire/ -- Tri-anim Health Services, a Sarnova company and a leading distributor of specialized respiratory, anesthesia, and critical care supplies, services and equipment, has been honored with the prestigious 2023 Zenith Award by the American Association for Respiratory Care (AARC).
  • This marks the fifth time that Tri-anim has won the Zenith Award (2023, 2021, 2020, 2018, and 2017).
  • The AARC Zenith Award is the "people's choice" award of the respiratory care profession because its recipients are chosen and voted upon by caregivers – the respiratory therapists.
  • Since 1975, Tri-anim has served as a specialty healthcare consultant and distributor of respiratory care, anesthesia, critical care and neonatal care supplies and equipment.

NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

Retrieved on: 
Thursday, October 26, 2023
FDA, Dark Enlightenment, IND, Chronic pain, Low back pain, DSM-IV codes, Addiction medicine, Pain management, DOD, Division, Clinical trial, Communication, Letter, Investigational New Drug, Pharmaceutical industry, Anesthesiology

The communication took the form of a "Study May Proceed" letter, authorizing NRx to proceed with opening a pharmacokinetic study under the newly-established Investigational New Drug file for treatment of Chronic Pain.

Key Points: 
  • The communication took the form of a "Study May Proceed" letter, authorizing NRx to proceed with opening a pharmacokinetic study under the newly-established Investigational New Drug file for treatment of Chronic Pain.
  • This is a formal letter that generally follows clearance of an IND and outlines nonclinical and clinical requirements suggested by the review division.
  • "We at NRx appreciate the rapid and supportive response from the FDA division that regulates pain products.
  • The identified nonclinical requirements should not pose a significant financial burden or time delay in initiating a registrational trial of NRX-101 for treatment of Chronic Pain, should the already-completed 200 person clinical trial yield encouraging data," said Stephen Willard, CEO of NRx Pharmaceuticals.

USF Health, Tampa General Again Expand Medical Training Opportunities to Strengthen Pipeline of Health Care Workforce

Retrieved on: 
Wednesday, October 25, 2023
TGH, Tampa General Hospital, Anesthesiology, Physician, Accreditation, Tampa, Florida, USF Health Byrd Alzheimer's Institute, Health, Research, Acquisition, Growth, GME, Student, Partnership, Surgery, University, TeamHealth, Accreditation Council, Graduate medical education, Anesthesia, Nursing, Dentistry, MD, Tampa Bay, Neuroscience

TAMPA, Fla., Oct. 25, 2023 /PRNewswire/ -- USF Health Morsani College of Medicine and Tampa General Hospital today announced the launch of a new medical residency training program in anesthesiology.

Key Points: 
  • Residents in the four-year program will work at Tampa General Hospital and other TGH locations throughout the Tampa Bay region and be trained by USF Health faculty.
  • The anesthesiology residents will add to the training positions already in place in MCOM's Graduate Medical Education (GME) program.
  • "In partnership with USF Health Morsani College of Medicine, we're continuing to expand training opportunities, strengthening the pipeline of talent to our region, and contributing to the exceptional care offered at Tampa General now and for years to come.
  • Tampa General, the primary teaching hospital for the USF Health Morsani College of Medicine, also supports the certified nurse anesthetist program based in the USF Health College of Nursing.

Dr. Harry Greenspun Joins Global Search Firm Calibre One

Retrieved on: 
Tuesday, October 24, 2023
Tufts University, Anesthesiology, Korn Ferry, Modern Healthcare, History of the University of Maryland, College Park, Grumman, Health, Healthcare Information and Management Systems Society, Government, HIMSS, AUC, Organization, Johns Hopkins Hospital, Environment, Dell, Veritas Capital, University, Northrop, Harvard University, Management, Dairy, Nursing, Health care, Greenspun, D.C

WASHINGTON, Oct. 24, 2023 /PRNewswire-PRWeb/ -- Calibre One, a leading global executive search boutique specializing in building leadership teams for innovators, entrepreneurs and companies undergoing technology or digital transformation, announces Harry Greenspun, M.D., has joined the team as partner, and he will lead Calibre One's new innovative health and well-being practice group while expanding the company's presence in the D.C. area.

Key Points: 
  • WASHINGTON, Oct. 24, 2023 /PRNewswire-PRWeb/ -- Calibre One, a leading global executive search boutique specializing in building leadership teams for innovators, entrepreneurs and companies undergoing technology or digital transformation, announces Harry Greenspun, M.D., has joined the team as partner, and he will lead Calibre One's new innovative health and well-being practice group while expanding the company's presence in the D.C. area.
  • An experienced chief medical officer himself, Greenspun has held executive roles at Deloitte, Dell, Northrop Grumman, Korn Ferry, and Guidehouse.
  • As a cardiac anesthesiologist, Greenspun has practiced in major academic medical centers, as well as community hospitals.
  • A resident of the D.C. area, Greenspun lives with his wife and sons and enjoys cycling, guitar, and supporting local youth athletic and music programs.

Philips Visual Patient Avatar pioneers at-a-glance patient data for faster, better decision-making in the operating room

Retrieved on: 
Friday, October 13, 2023
PHG, Partnership, American Society of Anesthesiologists, DRS, Perception, NYSE, Operating, Certified Registered Nurse Anesthetist, Structural load, BMC Medical Informatics and Decision Making, Philips, PST, MD, British Journal of Anaesthesia, Society, Safety, Hospital, patients, health, territories, ORS, Vital signs, Teaching hospital, Decision, Aircraft, Life, OR, Patient, AEX, Atmosphere, Hospital, Medical imaging, Nursing, Medical device, Anesthesiology

Visual Patient Avatar is designed to improve situational awareness with ground-breaking elegance by visualizing vital information through animations, colors and shapes.

Key Points: 
  • Visual Patient Avatar is designed to improve situational awareness with ground-breaking elegance by visualizing vital information through animations, colors and shapes.
  • By glancing at a monitor with Visual Patient Avatar, anesthesiologists and nurse anesthetists can recall and process critical data more quickly, efficiently and confidently – ultimately helping to save lives.
  • Visual Patient Avatar was designed in partnership with two clinicians at the Visualization Technology Research Group at the Institute of Anesthesiology, University Hospital of Zürich.
  • The inspiration for Visual Patient Avatar came from a hobby of the two clinicians, flying airplanes.

American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.

Retrieved on: 
Thursday, October 12, 2023
American Society of Anesthesiologists, Organization, Anesthesiology, Society, Health, FASA, Education, Anesthesia, Chronic pain, ASA, Patient, Nursing, FAAP

“We are delighted to establish this collaboration with Pacira, which we believe represents an excellent opportunity to advance education and innovation for our members,” said ASA President Michael Champeau, M.D., FAAP, FASA.

Key Points: 
  • “We are delighted to establish this collaboration with Pacira, which we believe represents an excellent opportunity to advance education and innovation for our members,” said ASA President Michael Champeau, M.D., FAAP, FASA.
  • Through the program, Pacira is supporting ASA’s major events, including this year’s ANESTHESIOLOGY® annual meeting, with valuable educational resources to improve patient care.
  • “Pacira is pleased to support ASA and we look forward to collaborating in our efforts to improve patient outcomes through opioid-minimizing strategies,” said Dave Stack, CEO and Chairman of Pacira.
  • We believe that working together, Pacira and the ASA can effect significant change in the best interest of patients.”
    Launched in 2010, ASA’s Industry Supporter Program is limited to 10 organizations at any time.

Masimo ORi™ Granted De Novo as the First and Only FDA-Cleared Noninvasive and Continuous Parameter to Provide Insight into Hyperoxia Under Supplemental Oxygen

Retrieved on: 
Friday, October 13, 2023
Surgery, Medical Devices, Hospitals, Health, Health Technology, Linda, Multimedia, MASI, Desaturation, De novo, US, University of Utah, De novo gene birth, MD, Ori, Motion, Blood gas tension, Apnea, University, Hyperoxia, Intensive care medicine, American Medical Association, FDA, CE marking, Masimo, Oxygen, Oxygen saturation (medicine), Anesthesia & Analgesia, Pulse, Airway management, Patient, Medical device, Compact Disc manufacturing, RD, Anesthesia, Anesthesiology, Pain management

Masimo (NASDAQ: MASI) today announced that ORi™, a noninvasive, continuous parameter designed to provide additional insight into a patient’s oxygen status in the moderate hyperoxic range under supplemental oxygen, has been granted a De Novo by the FDA.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that ORi™, a noninvasive, continuous parameter designed to provide additional insight into a patient’s oxygen status in the moderate hyperoxic range under supplemental oxygen, has been granted a De Novo by the FDA.
  • Enabled by the multi-wavelength Masimo rainbow® Pulse CO-Oximetry platform, ORi is designed for use in conjunction with oxygen saturation (SpO2) to provide increased resolution of changes in oxygenation under supplemental oxygen.
  • View the full release here: https://www.businesswire.com/news/home/20231013679815/en/
    Without ORi, there is no noninvasive way to monitor oxygenation under supplemental oxygen to manage hyperoxia, or higher than normal oxygenation of arterial blood.
  • By convention, SpO2 is limited to an upper limit of 100%, but oxygenation can rise into hyperoxia when supplemental oxygen is administered.

Coronis Health’s Fall 2023 Issue of Communiqué—Current News for the Anesthesia Specialty—Available Now

Retrieved on: 
Friday, October 13, 2023
Technology, Surgery, Hospitals, Accounting, Professional Services, Software, Practice Management, Health, General Health, News, Certified Registered Nurse Anesthetist, Sponsor, Anesthesiology, JD, Practice management, Bad News, The Companies (Model Articles) Regulations 2008, AKS, Pain management, Anti-Kickback Statute, Bad News (band), Surgeon, Nursing, Anesthesia, Coronis

Coronis Health (Coronis), a trusted name in anesthesia billing and practice management, is pleased to announce that the Fall 2023 issue of its quarterly newsletter, Communiqué, is now available.

Key Points: 
  • Coronis Health (Coronis), a trusted name in anesthesia billing and practice management, is pleased to announce that the Fall 2023 issue of its quarterly newsletter, Communiqué, is now available.
  • Communiqué is a publication dedicated to bringing practical and tangible articles and advice, specific to the anesthesia and pain management community.
  • Communiqué features articles focusing on the latest hot topics for anesthesiologists, nurse anesthetists, pain management specialists and anesthesia practice administrators.
  • Coronis Health offers Communiqué electronically, as well as in hard copy, both on a complimentary basis.